As EGFR is a well-validated molecular target and upstream activator of PI3K in HNSCC, we first sought to test the contribution of PIK3CA mutation to sensitivity/resistance to EGFR TKIs in HNSCC cell line models. Here, PIK3CA is linked to head and neck squamous cell carcinoma.